2022
Donor genetic and non-genetic factors affecting red blood cell transfusion effectiveness
Roubinian NH, Reese SE, Qiao H, Plimier C, Fang F, Page GP, Cable RG, Custer B, Gladwin MT, Goel R, Harris B, Hendrickson JE, Kanias T, Kleinman S, Mast AE, Sloan SR, Spencer BR, Spitalnik SL, Busch MP, Hod EA, . Donor genetic and non-genetic factors affecting red blood cell transfusion effectiveness. JCI Insight 2022, 7: e152598. PMID: 34793330, PMCID: PMC8765041, DOI: 10.1172/jci.insight.152598.Peer-Reviewed Original ResearchConceptsTransfusion effectivenessHemoglobin incrementsRBC transfusionG6PD deficiencyMulticenter retrospective studyRBC storage durationRBC unit transfusionPrecision medicine approachSubset of donorsTransfusion episodesTransfusion requirementsUnit transfusionRecipient factorsRetrospective studyRBC recipientsPatient outcomesRecipient characteristicsChild healthTransfusionVivo hemolysisTransfusion productsMedicine approachNon-genetic factorsOxidative hemolysisSingle nucleotide polymorphisms
2021
Management of hemolytic transfusion reactions
Hendrickson JE, Fasano RM. Management of hemolytic transfusion reactions. Hematology 2021, 2021: 704-709. PMID: 34889404, PMCID: PMC8791106, DOI: 10.1182/hematology.2021000308.Peer-Reviewed Original ResearchConceptsHemolytic transfusion reactionsRBC alloantibodiesSevere DHTRTransfusion reactionsRed blood cell transfusionDisease-specific risk factorsPathway activationMultiple RBC alloantibodiesBlood cell transfusionSymptoms of painStem cell transplantationSafety of transfusionSickle cell diseaseClassic pathway activationAlternative pathway activationTransfusion avoidanceCell transfusionCurative therapyCell transplantationPatient's hemoglobinRisk factorsTransfusion safetyCell diseaseDHTRHgb A
2017
A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia
Curtis SA, Curtis BR, Lee AI, Hendrickson JE, Lacy J, Podoltsev NA. A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia. Hematology 2017, 23: 429-432. PMID: 29281948, DOI: 10.1080/10245332.2017.1419600.Peer-Reviewed Original ResearchConceptsDrug-induced immune thrombocytopeniaAutoimmune hemolytic anemiaPlatelet-reactive antibodiesImmune thrombocytopeniaThrombotic microangiopathyAdministration of oxaliplatinCycles of FOLFOXOxaliplatin-induced thrombocytopeniaYear old manAnti-RBC IgGEvans syndromeAntibody testingFirst admissionIgM antibodiesSignificant thrombocytopeniaIgG antibodiesHemolytic anemiaThrombocytopeniaLeucovorinPlatelet IgGOlder menOxaliplatinSyndromeBlood centersPatients